Leukemia research最新文献

{"title":"Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial","authors":"Suisui Kan ,&nbsp;Hai Bai ,&nbsp;Hui Liu ,&nbsp;Jie Cui ,&nbsp;Xiaoyan Ke ,&nbsp;Huilai Zhang ,&nbsp;Lihong Liu ,&nbsp;Dongmei Yan ,&nbsp;Yongsheng Jiang ,&nbsp;Aimin Zang ,&nbsp;Junyuan Qi ,&nbsp;Li Wang ,&nbsp;Zhuogang Liu ,&nbsp;Bing Xu ,&nbsp;Ying Zhang ,&nbsp;Zhihui Zhang ,&nbsp;Xielan Zhao ,&nbsp;Chunhong Hu ,&nbsp;Shenmiao Yang ,&nbsp;Hui Zhou ,&nbsp;Mingzhi Zhang","doi":"10.1016/j.leukres.2024.107633","DOIUrl":"10.1016/j.leukres.2024.107633","url":null,"abstract":"<div><h3>Background</h3><div>Treating relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging. This report extends the three-year follow-up period for the phase Ⅱ YH-S001–04 trial, expanding upon the initial 15.8-month analysis.</div></div><div><h3>Methods</h3><div>Zimberelimab 240 mg was administered every two weeks for two years or until disease progression or death. The endpoint was the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>The median follow-up was 38.0 months (3.5–42.8 months). The ORR was 91.6 % (95 % CI, 83.8–95.9). Median PFS was 23.6 months, with a longer PFS in responders (28.5 months) compared to non-responders (9.2 months) (<em>P</em>=0.0098). Complete responders had longer mPFS than partial responders (Not reached vs. 28.5 months, <em>P</em>=0.3469). Relapsed patients had improved mPFS compared to refractory cHL (23.6 vs. 10.6 months, <em>P</em>=0.0061). Patients with ＜3 lines of therapy showed longer mPFS compared to ≥3 lines (not reached vs. 23.6 months, <em>P</em>=0.0095). The 3-year OS rate was 94.0 % (95 % CI, 85.9–97.4). No serious adverse events with incidence &gt;5 %.</div></div><div><h3>Conclusions</h3><div>With encouraging data on both PFS and OS, zimberelimab demonstrates ongoing efficacy and safety in treating R/R cHL, supporting zimberelimab as an effective treatment alternative for R/R cHL (NCT03655483).</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"149 ","pages":"Article 107633"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally","authors":"Noriaki Yoshida ,&nbsp;Ayumi Hida ,&nbsp;Ritsu Sakata","doi":"10.1016/j.leukres.2025.107654","DOIUrl":"10.1016/j.leukres.2025.107654","url":null,"abstract":"<div><div>Human T-cell leukemia virus type 1 (HTLV-1) has been identified as a cause of adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite several HTLV-1 endemic areas being identified, comprehensive investigations have yet to be conducted in all the regions of the world. This review aims to summarize the current reports on HTLV-1. As vertical transmission is known to be a risk factor for ATL development, prevention strategies have been initiated in Japan, and these efforts may be related to the decrease in the estimated number of HTLV-1 carriers in Japan. In numerous HTLV-1 endemic regions, the prevalence of HTLV-1 increases with age, which may be attributed to horizontal infection. However, the incidence of HTLV-1 infection appears to be high among adolescents and young adults in Japan, especially in non-endemic areas. The clinical significance of HTLV-1 infections, other than ATL and HAM/TSP, has recently been documented. Consequently, it is imperative to develop treatment strategies for HTLV-1 infections, including measures to prevent horizontal infections.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"150 ","pages":"Article 107654"},"PeriodicalIF":2.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy","authors":"Sawyer Bawek,&nbsp;Matthew Burwinkel,&nbsp;Prutha Patel,&nbsp;Katy Wang,&nbsp;Kristopher Attwood,&nbsp;Tara Cronin,&nbsp;Melissa Fos,&nbsp;Steven Green,&nbsp;Pamela J. Sung,&nbsp;James E. Thompson,&nbsp;Elizabeth A. Griffiths,&nbsp;Eunice S. Wang,&nbsp;Amanda C. Przespolewski","doi":"10.1016/j.leukres.2025.107643","DOIUrl":"10.1016/j.leukres.2025.107643","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"150 ","pages":"Article 107643"},"PeriodicalIF":2.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood cancer therapy with synthetic receptors and CRISPR technology","authors":"Haiying Zhang ,&nbsp;Mingxin Zhong ,&nbsp;Jingdong Zhang ,&nbsp;Changkun Chen","doi":"10.1016/j.leukres.2025.107646","DOIUrl":"10.1016/j.leukres.2025.107646","url":null,"abstract":"<div><div>Chimeric antigen receptor (CAR)-T and -NK cells showed great success in treating hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR technology and other synthetic receptors (GPCR and synNotch) have helped to address some of the limitations and challenges associated with CAR-based therapies. Herein, this review aims to discuss how CAR can be integrated with other synthetic receptors and various CRISPR/Cas tools for blood cancer therapy. CAR-expressing cells equipped with other synthetic receptors can conditionally execute tumoricidal functions, prevent tumor escape from immune surveillance, and minimize non-tumor off-target toxicity. We also discussed how various CRISPR-Cas tools can be harnessed to enhance CAR cells functionality and persistence. The advances, pitfalls, and future perspectives for these synthetic receptors and CRISPR technology in blood cancer therapy are comprehensively discussed.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"150 ","pages":"Article 107646"},"PeriodicalIF":2.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143229974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis","authors":"Moazzam Shahzad ,&nbsp;Qamar Iqbal ,&nbsp;Muhammad Kashif Amin ,&nbsp;Sohaib Irfan ,&nbsp;Sarmad Zaman Warraich ,&nbsp;Iqra Anwar ,&nbsp;Prashil Dave ,&nbsp;Ahmad Basharat ,&nbsp;Ahmed Hebishy ,&nbsp;Muhammad Salman Faisal ,&nbsp;Michael Jaglal ,&nbsp;Muhammad Umair Mushtaq","doi":"10.1016/j.leukres.2024.107640","DOIUrl":"10.1016/j.leukres.2024.107640","url":null,"abstract":"<div><h3>Background</h3><div>Hematopoietic stem cell transplantation (HCT) is a pivotal treatment modality for primary plasma cell leukemia (pPCL). We aimed to examine the outcomes of allogeneic (allo) and autologous (auto) HCT in adult pPCL patients.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines, a comprehensive literature search was performed on PubMed, Cochrane, Embase, and Clinicaltrials.gov using relevant MeSH terms and keywords. Twelve original articles reporting outcomes of auto-HCT or allo-HCT in adult pPCL patients were included. The pooled analysis was performed using the ‘meta’ package in the R program (version 4.3.0).</div></div><div><h3>Results</h3><div>Our analysis included 1757 pPCL patients (1535 with auto-HCT, 222 with allo-HCT), and 49 % were males. The pooled 3 years overall survival (OS), progression-free survival/event-free survival (PFS/EFS), and relapse rate (RR) in auto-HCT were 51 % (95 % CI 0.4–0.61, I²=92 %, p = &lt;0.01), 36 % (95 % CI 0.24–0.52, I 2 =97 %, p &lt; 0.01), and 68 % (95 % CI, 0.65–0.71, I2=0 %, p = 0.42), respectively. Among allo-HCT recipients, the reported OS varied from 71 % at 2.3 years to 31 % at 4 years and EFS/PFS from 29 % at 2.5 years to 19 % at 4 years. The pooled treatment-related mortality (TRM) was 12 % (95 % CI 0.05–0.25, I ²=35 %, p = 0.22) at a median of 6 months. The pooled incidence of acute and chronic graft versus host disease was 27 % (0.19–0.36, I²= 30 %, p = 0.21) and 36 % (0.27–0.45, I²= 24 %, p = 0.26), respectively.</div></div><div><h3>Conclusion</h3><div>HCT remains pivotal in treating primary plasma cell leukemia. However, higher relapse rates warrant novel agents and clinical trials to improve transplant-related outcomes in this challenging subgroup.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107640"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The increase in the expression of circRNAs may contributes to a poor prognosis in acute myeloid leukemia: A systematic review and meta-analysis","authors":"Meng Li ,&nbsp;Shiming Zhang ,&nbsp;Junfan Wei ,&nbsp;Mengfei Liu ,&nbsp;Bohao Zhang ,&nbsp;Shen Li ,&nbsp;Yue Xiao ,&nbsp;Yuandong Yu ,&nbsp;Ruipeng Song","doi":"10.1016/j.leukres.2024.107639","DOIUrl":"10.1016/j.leukres.2024.107639","url":null,"abstract":"<div><h3>Objective</h3><div>The primary methods for defining the prognostic risk of AML patients are cytogenetic and molecular analysis at the time of diagnosis. However, the prognosis of intermediate-risk patients is still not well assessed for biomarkers. The main objective of this meta-analysis is to evaluate the relationship between circRNAs and AML prognosis, to provide a theoretical basis for finding effective prognostic indicators in intermediate-risk patients, and to provide an important scientific basis for the development or revision of WHO practice guidelines and ELN risk classification, and to highlight the importance of continuing to focus on and evaluate the prognostic impact of circRNAs on AML in future studies.</div></div><div><h3>Methods</h3><div>We performed a comprehensive literature search across PubMed, the Cochrane Library, and Web of Science databases for studies published up to September 15, 2024. Articles were selected based on inclusion criteria. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of studies. The outcome measure of overall survival (OS) was used, and hazard ratios (HR) and 95 % confidence intervals (CI) were pooled to estimate the relationship between circRNA expression and prognosis in AML using STATA 17.0 software.</div></div><div><h3>Results</h3><div>A total of 13 studies involving 1401 AML patients were included. The studies showed a significantly increased hazard ratio (HR) of upregulated CircRNA expression for OS (HR=1.87, 95 % CI=1.51–2.32, <em>P</em> &lt; 0.001). The results of subgroups analysis showed a significant increase in the hazard ratio (HR) for upregulation of CircRNA expression in EFS and circ_0012152（HR= 1.66, 95 % CI= 1.19–2.32, <em>P</em> &lt; 0.005 and HR= 2.26,95 % CI= 1.27–4.00, <em>P</em> &lt; 0.005), respectively. No significant heterogeneity or publication bias was detected.</div></div><div><h3>Conclusion</h3><div>Upregulated circRNA expression is significantly associated with poor prognosis in AML patients and may serve as a prognostic marker for AML.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107639"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)","authors":"Devon A. Weterings ,&nbsp;Aileen G. Rowan ,&nbsp;Lucy B. Cook","doi":"10.1016/j.leukres.2024.107635","DOIUrl":"10.1016/j.leukres.2024.107635","url":null,"abstract":"<div><div>Human T-cell leukaemia virus type-1 (HTLV-1) causes the highly aggressive malignancy adult T-cell leukaemia-lymphoma (ATL) in approximately 5 % of chronically infected carriers. HTLV-1 persists in the host by enhancing survival of infected-T-cells despite the presence of a strong immune response. Therefore, asymptomatic HTLV-1 carriers have a lifelong balance between infected cell proliferation and the host antiviral immune response. However, this immunological balance is lost in patients with ATL. Reliable treatment options are lacking and there is urgent need for new treatment strategies to improve the dismal prognosis of ATL. In this review, we present a summary of the current knowledge on the immunological aspects of HTLV-1 persistence and the immune alterations observed in ATL, and discuss how the recent emerging advances in adoptive immunotherapy may offer a prevention and treatment option for ATL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107635"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era","authors":"Kennosuke Karube ,&nbsp;Shugo Sakihama ,&nbsp;Mitsuyoshi Takatori ,&nbsp;Kazuho Morichika ,&nbsp;Tomoko Tamaki ,&nbsp;Naoki Wada ,&nbsp;Takuya Fukushima","doi":"10.1016/j.leukres.2024.107634","DOIUrl":"10.1016/j.leukres.2024.107634","url":null,"abstract":"<div><div>Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by Human T-cell leukemia virus type 1 (HTLV-1) infection. Although the 5th Edition of the WHO classification (WHO-5) did not make drastic changes regarding the disease concept of ATLL from the revised 4th Edition of the WHO classification (WHO-4R), WHO-5 newly introduced the essential and desirable diagnostic criteria, namely, \"neoplastic lymphoid cell proliferation with mature T-cell phenotype; proven HTLV-1 carriership\" and \"identification of monoclonal integration of HTLV-1\", respectively. To satisfy the desirable criteria, a new diagnostic method using a combination of HBZ-ISH and tax-PCR was introduced for the identification of the HTLV-1 in addition to the conventionally used Southern blot hybridization, especially in the case when only FFPE specimens are available. Morphologically, pleomorphic- and anaplastic large cell-type, account for most cases, while minor variants, ATLL with dermatopathic reaction, angioimmunoblastic T-cell lymphoma-like variant, and classic Hodgkin lymphoma-like variant, should also be noted as diagnostic pitfalls. Phenotypically, about 80 % of ATLL cases show a typical phenotype of CD3 + CD4 +CD25 +CCR4 + , while about 10 % show atypical phenotypes such as T follicular helper cell-like one. Many genetic abnormalities, mainly associated with the TCR signaling pathway, are observed, and most are more frequent in the aggressive type than in the indolent type, except for <em>STAT3</em>, indicating the heterogeneous pathogenic process of ATLL. In this review, we present the latest findings on molecular pathogenesis and histopathological findings of ATLL in the era of the new classification of lymphomas, serving as a basis for future research and classification.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107634"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy","authors":"Juan Li ,&nbsp;Shuying Fu ,&nbsp;Chunmei Ye ,&nbsp;Jun Li","doi":"10.1016/j.leukres.2024.107638","DOIUrl":"10.1016/j.leukres.2024.107638","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a complex hematological malignancy predominantly affecting the elderly, with a median diagnosis age of 68 years. Despite advances in treatment, elderly AML patients face suboptimal survival outcomes, with an estimated 5-year survival rate below 20 %. Epigenetic dysregulation, notably DNA methylation, is a key factor in the progression of myelodysplastic syndromes (MDS) to AML. This review examines various combination regimens involving azacitidine (AZA), including those with lenalidomide, histone deacetylase inhibitors (HDACi), kinase inhibitors, metabolic enzyme inhibitors, monoclonal antibodies, immune checkpoint inhibitors, and anti-apoptotic protein inhibitors. Notable among these are the combinations with venetoclax, which has demonstrated remarkable efficacy in phase III trials, and the emerging IDH inhibitors ivosidenib and enasidenib, which have shown significant clinical benefits in patients with IDH mutations. While combination therapies with AZA hold great promise, challenges persist, including translating in vitro synergies to in vivo efficacy and identifying optimal regimens for specific patient populations. Cumulative toxicities may also offset clinical benefits, necessitating rigorous clinical trial design. Future research must focus on refining combination strategies, optimizing dosages and sequences, and thoroughly evaluating therapeutic efficacy and safety to advance the treatment of AML and improve patient outcomes.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107638"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques","authors":"Maedeh Rouzbahani ,&nbsp;Seyed Amirhossein Mousavi ,&nbsp;Ghasem Hajianfar ,&nbsp;Ali Ghanaati ,&nbsp;Mohammad Vaezi ,&nbsp;Ardeshir Ghavamzadeh ,&nbsp;Maryam Barkhordar","doi":"10.1016/j.leukres.2024.107619","DOIUrl":"10.1016/j.leukres.2024.107619","url":null,"abstract":"<div><h3>Background</h3><div>Leukemia necessitates continuous research for effective therapeutic techniques. Acute leukemia (AL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) focus on key outcomes such as overall survival (OS), relapse, and graft-versus-host disease (GVHD).</div></div><div><h3>Objective</h3><div>This study aims to evaluate the capability of machine learning (ML) models in predicting OS, relapse, and GVHD in AL patients post-allo-HSCT.</div></div><div><h3>Methods</h3><div>Clinical data from 1243 AL patients, with 10 years of follow-up, was utilized to develop 28 ML models. These models incorporated four feature selection methods and seven ML algorithms. Model performance was assessed using the concordance index (c-index) with multivariate analysis.</div></div><div><h3>Results</h3><div>The multivariate model analysis showed the best FS/ML combinations were UCI_GLMN, IBMA_GLMN and IBMA_CB for OS, UCI_ST, UCI_RSF, UCI GLMB, UCI_GB, UCI_CB, MI_GLMN, IBMA_ST and IBMA GB for relapse, IBMA_GB for aGVHD and Boruta_GB for cGVHD (all p values &lt; 0.0001, mean C-indices in 0.61–0.68)).</div></div><div><h3>Conclusion</h3><div>ML techniques, when combined with clinical variables, demonstrate high accuracy in predicting OS, relapse, and GVHD in AL patients.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107619"},"PeriodicalIF":2.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}